Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3861 | KRT14 | GSM5252132_BPH389PrGF | Human | Prostate | BPH | 1.77e-03 | 2.55e+00 | -0.2247 |
3861 | KRT14 | GSM5252134_BPH511PrG_Fcol_3GEX | Human | Prostate | BPH | 1.33e-03 | 1.45e+00 | -0.1433 |
3861 | KRT14 | GSM5252135_BPH511PrPUr_Fcol_3GEX | Human | Prostate | BPH | 1.78e-06 | 1.08e+00 | -0.1833 |
3861 | KRT14 | GSM5252136_BPH556PrGA1_Fcol | Human | Prostate | BPH | 7.18e-23 | 2.28e+00 | -0.23 |
3861 | KRT14 | GSM5252137_BPH556PrGA2_Fcol | Human | Prostate | BPH | 6.35e-23 | 3.61e+00 | -0.23 |
3861 | KRT14 | 052099_1652-all-cells | Human | Prostate | BPH | 3.00e-04 | 1.18e-01 | 0.1038 |
3861 | KRT14 | Dong_P1 | Human | Prostate | Tumor | 1.18e-25 | -8.41e-01 | 0.035 |
3861 | KRT14 | Dong_P3 | Human | Prostate | Tumor | 1.21e-05 | 3.44e-01 | 0.0278 |
3861 | KRT14 | Dong_P4 | Human | Prostate | Tumor | 5.50e-04 | -9.16e-01 | 0.0292 |
3861 | KRT14 | Dong_P5 | Human | Prostate | Tumor | 2.23e-23 | -8.52e-01 | 0.053 |
3861 | KRT14 | P7 | Human | Prostate | Tumor | 4.92e-03 | -3.03e-01 | -0.1025 |
3861 | KRT14 | P9 | Human | Prostate | Tumor | 5.01e-08 | -8.54e-01 | -0.0285 |
3861 | KRT14 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 2.64e-02 | -6.71e-01 | 0.1633 |
3861 | KRT14 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 1.27e-09 | -8.50e-01 | 0.1608 |
3861 | KRT14 | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 7.18e-04 | -8.04e-01 | 0.1604 |
3861 | KRT14 | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 8.07e-07 | -8.20e-01 | 0.1602 |
3861 | KRT14 | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 8.71e-10 | -7.96e-01 | 0.1575 |
3861 | KRT14 | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 3.38e-02 | 3.20e-01 | 0.1545 |
3861 | KRT14 | P1_S1_AK | Human | Skin | AK | 1.36e-17 | 2.72e-01 | -0.3399 |
3861 | KRT14 | P2_S3_AK | Human | Skin | AK | 2.66e-17 | 3.13e-01 | -0.3287 |
Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/KRT14_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/KRT14_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/KRT14_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/KRT14_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/KRT14_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/KRT14_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0491518 | Breast | Precancer | Estrogen signaling pathway | 28/684 | 138/8465 | 4.10e-06 | 5.39e-05 | 4.13e-05 | 28 |
hsa0491519 | Breast | Precancer | Estrogen signaling pathway | 28/684 | 138/8465 | 4.10e-06 | 5.39e-05 | 4.13e-05 | 28 |
hsa0491523 | Breast | IDC | Estrogen signaling pathway | 35/867 | 138/8465 | 2.55e-07 | 5.18e-06 | 3.88e-06 | 35 |
hsa0491533 | Breast | IDC | Estrogen signaling pathway | 35/867 | 138/8465 | 2.55e-07 | 5.18e-06 | 3.88e-06 | 35 |
hsa0491542 | Breast | DCIS | Estrogen signaling pathway | 35/846 | 138/8465 | 1.40e-07 | 2.51e-06 | 1.85e-06 | 35 |
hsa05150 | Breast | DCIS | Staphylococcus aureus infection | 19/846 | 96/8465 | 2.68e-03 | 1.67e-02 | 1.23e-02 | 19 |
hsa0491552 | Breast | DCIS | Estrogen signaling pathway | 35/846 | 138/8465 | 1.40e-07 | 2.51e-06 | 1.85e-06 | 35 |
hsa051501 | Breast | DCIS | Staphylococcus aureus infection | 19/846 | 96/8465 | 2.68e-03 | 1.67e-02 | 1.23e-02 | 19 |
hsa0491520 | Cervix | CC | Estrogen signaling pathway | 44/1267 | 138/8465 | 3.55e-07 | 3.97e-06 | 2.35e-06 | 44 |
hsa04915110 | Cervix | CC | Estrogen signaling pathway | 44/1267 | 138/8465 | 3.55e-07 | 3.97e-06 | 2.35e-06 | 44 |
hsa051504 | Cervix | HSIL_HPV | Staphylococcus aureus infection | 21/459 | 96/8465 | 2.93e-08 | 1.43e-06 | 1.16e-06 | 21 |
hsa0491524 | Cervix | HSIL_HPV | Estrogen signaling pathway | 19/459 | 138/8465 | 1.54e-04 | 1.74e-03 | 1.40e-03 | 19 |
hsa0515011 | Cervix | HSIL_HPV | Staphylococcus aureus infection | 21/459 | 96/8465 | 2.93e-08 | 1.43e-06 | 1.16e-06 | 21 |
hsa0491534 | Cervix | HSIL_HPV | Estrogen signaling pathway | 19/459 | 138/8465 | 1.54e-04 | 1.74e-03 | 1.40e-03 | 19 |
hsa051502 | Cervix | N_HPV | Staphylococcus aureus infection | 15/349 | 96/8465 | 7.81e-06 | 1.01e-04 | 7.90e-05 | 15 |
hsa0491543 | Cervix | N_HPV | Estrogen signaling pathway | 16/349 | 138/8465 | 1.68e-04 | 1.53e-03 | 1.19e-03 | 16 |
hsa051503 | Cervix | N_HPV | Staphylococcus aureus infection | 15/349 | 96/8465 | 7.81e-06 | 1.01e-04 | 7.90e-05 | 15 |
hsa0491553 | Cervix | N_HPV | Estrogen signaling pathway | 16/349 | 138/8465 | 1.68e-04 | 1.53e-03 | 1.19e-03 | 16 |
hsa0491529 | Oral cavity | EOLP | Estrogen signaling pathway | 38/1218 | 138/8465 | 3.78e-05 | 1.82e-04 | 1.07e-04 | 38 |
hsa04915113 | Oral cavity | EOLP | Estrogen signaling pathway | 38/1218 | 138/8465 | 3.78e-05 | 1.82e-04 | 1.07e-04 | 38 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KRT14 | SNV | Missense_Mutation | | c.1369N>A | p.Asp457Asn | p.D457N | P02533 | protein_coding | tolerated(0.14) | benign(0.211) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KRT14 | SNV | Missense_Mutation | | c.611A>G | p.Tyr204Cys | p.Y204C | P02533 | protein_coding | deleterious(0) | benign(0.316) | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
KRT14 | SNV | Missense_Mutation | rs769859839 | c.1330T>C | p.Ser444Pro | p.S444P | P02533 | protein_coding | tolerated(0.15) | possibly_damaging(0.616) | TCGA-AR-A1AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
KRT14 | SNV | Missense_Mutation | rs775441985 | c.1327N>C | p.Ser443Pro | p.S443P | P02533 | protein_coding | tolerated(0.29) | possibly_damaging(0.506) | TCGA-B6-A1KF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KRT14 | SNV | Missense_Mutation | novel | c.824N>T | p.Ala275Val | p.A275V | P02533 | protein_coding | deleterious(0.02) | probably_damaging(0.951) | TCGA-B6-A40C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | cyclophosphamide | SD |
KRT14 | insertion | In_Frame_Ins | novel | c.770_771insTGCTGTTGTGGTCAGCACCATGAACAG | p.Met257delinsIleAlaValValValSerThrMetAsnArg | p.M257delinsIAVVVSTMNR | P02533 | protein_coding | | | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
KRT14 | insertion | Frame_Shift_Ins | novel | c.294_295insAACGGGACCAGGCAAG | p.Gly99AsnfsTer15 | p.G99Nfs*15 | P02533 | protein_coding | | | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
KRT14 | insertion | Frame_Shift_Ins | novel | c.1130_1131insACTCCTGATTAGTCCATTGTCTGTCCACC | p.Gly378LeufsTer37 | p.G378Lfs*37 | P02533 | protein_coding | | | TCGA-BH-A0BD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
KRT14 | insertion | Frame_Shift_Ins | novel | c.484_485insCTATAGGACAGAGTCCACCCCAGATCCCTTCTTTCGAGGTCTTGGA | p.Tyr162SerfsTer24 | p.Y162Sfs*24 | P02533 | protein_coding | | | TCGA-BH-A0DS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide | SD |
KRT14 | SNV | Missense_Mutation | novel | c.797G>A | p.Gly266Glu | p.G266E | P02533 | protein_coding | deleterious(0.01) | probably_damaging(0.914) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |